Insight Into Factors Governing Formation, Synthesis and Stereochemical Configuration of DNA Adducts Formed by...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Biochemistry

Background:

• Mitomycin C (MC) is an antitumor drug functioning as a DNA alkylating agent.
• MC requires reductive activation to reactive mitosenes, which form DNA monoadducts and interstrand crosslinks (ICLs).
• The established view of MC primarily targeting CpG sequences has been recently challenged.

Purpose of the Study:

• To review the latest research on DNA alkylation by Mitomycin C (MC) and dicarbamoylmitomycin C (DMC).
• To investigate the regioselectivity of mitomycins DNA alkylation and its link to reductive activation pathways and adduct stereochemistry.
• To explore synthetic routes for MC/DMC DNA adducts and their role in drug cytotoxicity.

Main Methods:

• Review of recent scientific literature on Mitomycin C and DMC DNA adducts.
• Investigation of synthetic pathways to generate site-specific MC/DMC nucleoside adducts and oligonucleotides.
• Analysis of DNA structural modifications induced by MC/DMC adducts.

Main Results:

• Mitomycin C and DMC alkylate DNA, forming monoadducts and ICLs, contributing to cytotoxicity.
• New research indicates mitomycins may target DNA sequences beyond CpG.
• The study explores the relationship between reductive activation, DNA adduct stereochemistry, and regioselectivity.

Conclusions:

• Understanding mitomycins DNA alkylation mechanisms, including regioselectivity and stereochemistry, is crucial for drug development.
• Site-specifically modified oligonucleotides are valuable tools for elucidating the role of specific adducts in MC/DMC cytotoxicity.
• Further research is needed to fully elucidate the complex interactions between mitomycins, DNA, and cellular responses.